Contact
Please use this form to send email to PR contact of this press release:
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
TO:
Please use this form to send email to PR contact of this press release:
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
TO: